Serum resistin and the risk for hepatocellular carcinoma in diabetic patients

doi:10.3748/wjg.v29.i27.4271

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 27

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3223)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

WORD

HTML

1466

Figures (1-2)

270

Tables (1-1)

246

Sum=2080

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

122

Download

321

Sum=443

Publishing Process of This Article

Item

Count

Browse

163

Download

394

Sum=557

Jul 21, 2023 (publication date) through May 16, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jul 21, 2023; 29(27): 4271-4288
Published online Jul 21, 2023. doi: 10.3748/wjg.v29.i27.4271

Full Size Figure Download Figure

Figure 1 Factors contributing to increased risk of hepatocellular carcinoma in diabetic patients. NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; HCC: Hepatocellular carcinoma.

Citation: Abdalla MMI. Serum resistin and the risk for hepatocellular carcinoma in diabetic patients. World J Gastroenterol 2023; 29(27): 4271-4288
URL: https://www.wjgnet.com/1007-9327/full/v29/i27/4271.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i27.4271